Peterson Wealth Services Reduces Position in DexCom, Inc. $DXCM

Peterson Wealth Services lessened its stake in DexCom, Inc. (NASDAQ:DXCM) by 80.9% in the fourth quarter, HoldingsChannel reports. The firm owned 5,539 shares of the medical device company’s stock after selling 23,398 shares during the period. Peterson Wealth Services’ holdings in DexCom were worth $368,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Banco BTG Pactual S.A. purchased a new position in DexCom in the fourth quarter worth about $1,350,000. Caerus Investment Advisors LLC purchased a new position in DexCom in the fourth quarter worth about $342,000. ICICI Prudential Asset Management Co Ltd boosted its position in DexCom by 3.9% in the fourth quarter. ICICI Prudential Asset Management Co Ltd now owns 6,259 shares of the medical device company’s stock worth $415,000 after purchasing an additional 237 shares during the last quarter. Xponance LLC boosted its position in DexCom by 5.4% in the fourth quarter. Xponance LLC now owns 97,920 shares of the medical device company’s stock worth $6,499,000 after purchasing an additional 5,021 shares during the last quarter. Finally, Keel Point LLC boosted its position in DexCom by 3.1% in the fourth quarter. Keel Point LLC now owns 6,473 shares of the medical device company’s stock worth $430,000 after purchasing an additional 193 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on DXCM shares. Sanford C. Bernstein set a $77.00 price target on shares of DexCom in a research note on Friday, May 1st. Wall Street Zen cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 10th. Truist Financial reiterated a “buy” rating and set a $80.00 price target (down from $82.00) on shares of DexCom in a research note on Tuesday, February 17th. Citigroup reaffirmed a “buy” rating and set a $84.00 price objective (up from $79.00) on shares of DexCom in a research report on Thursday, May 28th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of DexCom in a research report on Monday, June 1st. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $84.29.

Insider Activity

In related news, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total value of $60,730.12. Following the transaction, the director directly owned 25,007 shares of the company’s stock, valued at approximately $1,500,670.07. The trade was a 3.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,912 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $73.00, for a total value of $358,576.00. Following the completion of the transaction, the executive vice president directly owned 100,361 shares in the company, valued at approximately $7,326,353. This represents a 4.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 42,694 shares of company stock worth $3,029,267 in the last quarter. Corporate insiders own 0.28% of the company’s stock.

DexCom Stock Up 0.6%

DXCM opened at $75.25 on Friday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $89.98. The firm’s fifty day moving average is $65.87 and its 200 day moving average is $67.50. The stock has a market cap of $29.04 billion, a price-to-earnings ratio of 32.16, a price-to-earnings-growth ratio of 1.17 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter in the previous year, the company earned $0.32 EPS. DexCom’s revenue for the quarter was up 15.0% on a year-over-year basis. On average, sell-side analysts forecast that DexCom, Inc. will post 2.58 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.